Loading
This study tests a PARP inhibitor; the registry reports that it is recruiting.
The registry lists NCT06907043 as recruiting, last updated 2025-08-19. Enrolment is 130 planned participants, an estimate. Interventions: EIK1004-001 (IMP1707-001). Primary measures include Number of Participants who experience a Dose-Limiting Toxicity (DLT); Number of participants with adverse events, treatment emergent adverse events or serious adverse events. No results are posted in the registry; this does not exclude separate publications.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares IMPACT Therapeutics, Eikon Therapeutics, PARP, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares IMPACT Therapeutics, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares IMPACT Therapeutics, PARP and the tag pipeline.
Shares PARP, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Eikon Therapeutics and the tag pipeline.
Shares Eikon Therapeutics and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/